<scp>TSLP</scp>,<scp> IL</scp>‐31, <scp>IL</scp>‐33 and <scp>sST</scp>2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis

Nygaard, Uffe; Hvid, Malene; Johansen, Claus; Buchner, Matthias; Fölster‐Holst, Regina; Deleuran, Mette; Vestergaard, Christian

doi:10.1111/jdv.13679

Cited by 132 publications

(122 citation statements)

References 57 publications

(73 reference statements)

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…Elevation of the Th2/Th1-associated cytokines and chemokines in atopic dermatitis lesions is well appreciated [22], although it had not previously been reported in a wheat allergy-associated dermatitis mouse model [23]. Here we report elevation of these Th2/Th1-associated cytokines and chemokines in the dermatitis lesion.…”

Section: Discussionsupporting

confidence: 48%

A Mouse Model of Anaphylaxis and Atopic Dermatitis to Salt-Soluble Wheat Protein Extract

Jin

Ebaugh

Martens

et al. 2017

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Wheat allergy and other immune-mediated disorders triggered by wheat proteins are growing at an alarming rate for reasons not well understood. A mouse model to study hypersensitivity responses to salt-soluble wheat protein (SSWP) extract is currently unavailable. Here we tested the hypothesis that SSWP extract from wheat will induce sensitization as well as allergic disease in mice. Methods: Female BALB/cJ mice were weaned onto a plant protein-free diet. The mice were injected a total of 4 times with an SSWP (0.01 mg/mouse) fraction extracted from durum wheat along with alum as an adjuvant. Blood was collected biweekly and SSWP-specific IgE (SIgE) and total IgE (TIgE) levels were measured using ELISA. Systemic anaphylaxis upon intraperitoneal injection with SSWP was quantified by hypothermia shock response (HSR). Mucosal mast cell degranulation was measured by the elevation of mMCP-1 in the blood. The mice were monitored for dermatitis. Skin tissues were used in histopathology and for measuring cytokine/chemokine/adhesion molecule levels using a protein microarray system. Results: Injection with SSWP resulted in time-dependent SIgE antibody responses associated with the elevation of TIgE concentration. Challenge with SSWP elicited severe HSR that correlated with a significant elevation of plasma mMCP-1 levels. Sensitized mice developed facial dermatitis associated with mast cell degranulation. Lesions expressed significant elevation of Th2/Th17/Th1 cytokines and chemokines and E-selectin adhesion molecule. Conclusion: Here we report a mouse model of anaphylaxis and atopic dermatitis to SSWP extract that may be used for further basic and applied research on wheat allergy.

show abstract

Section: Discussionsupporting

confidence: 48%

A Mouse Model of Anaphylaxis and Atopic Dermatitis to Salt-Soluble Wheat Protein Extract

Jin

Ebaugh

Martens

et al. 2017

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…45 And a recent cross-sectional study of Nygaard et al that included 163 adults and children with AD, was unable to confirm the correlation between serum IL-31 and disease severity. 46 Kim et al found that IL-31 mRNA expression is higher in biopsies from AD patients with high pruritus scores compared to patients with low pruritus scores, 47 suggesting that measurement of IL-31 in skin may be a more relevant measure for itch. Although IL-31 expression patterns in skin biopsies may also be extremely helpful in stratification, skin biopsies are invasive, require trained personnel and specialized labs.…”

Section: Biomarker For Itchmentioning

confidence: 99%

Biomarkers for atopic dermatitis

Thijs

Krastev

Weidinger

et al. 2015

Current Opinion in Allergy &Amp; Clinical Immunology

184

View full text Add to dashboard Cite

“…The rationale behind targeted IL-17A therapy is the emerging evidence that Th17 T cells play a potentially greater part in the AD-related immune activation, including attraction of neutrophils, than thought earlier [10,46,47]. Especially the subgroup of the AD population with low IgE and increased Th17 cell activation might be responsive to such therapy [25].…”

Section: Anti-interleukin-17amentioning

confidence: 99%

“…Targeting key mediators of disease, either via narrow isolated effects or broader downstream actions, is a potential means to alleviate the disease. Targeted and personalized therapy based on endophenotypic profiling and a greater comprehension of the pathogenesis of AD is the next step for drug development in AD [10,[20][21][22][23][24].…”

Section: Immunopathology Of Admentioning

confidence: 99%

Emerging Treatment Options in Atopic Dermatitis: Systemic Therapies

Nygaard

Vestergaard

Deleuran³

2017

Dermatology

View full text Add to dashboard Cite

The pathogenesis of atopic dermatitis (AD) is multifactorial and intricate, and the clinical presentation of the condition varies greatly. Symptoms and severity depend on individual trigger factors and stage of the disease. The majority of AD patients are sufficiently treated with emollients in combination with existing topical or systemic therapies. Yet treatment failure with existing drugs and treatment options can be a significant clinical problem. New treatments are under development, and the majority of these new drugs focus on targeting a skewed immune response in AD. Novel therapeutic approaches, which target the pathways involved in the pathogenesis of AD, may provide a potentially more effective and less harmful approach to systemic therapy. These pharmaceutical agents are designed to narrowly modify or directly block a specific cellular signal or pro-inflammatory pathway. We review systemic drugs in the pipeline for AD. To make the review as current and pertinent as possible, we selected to focus on AD-related therapies available in the clinicaltrials.gov database with a first received date after January 1, 2014, up until May 31, 2017. We excluded therapies that could be categorized as either traditional Chinese medicine, herbal medicine, probiotics, histamine/leukotriene blockers, immuno-adsorption, or immunostimulants.

show abstract

TSLP, IL‐31, IL‐33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis

Cited by 132 publications

References 57 publications

A Mouse Model of Anaphylaxis and Atopic Dermatitis to Salt-Soluble Wheat Protein Extract

A Mouse Model of Anaphylaxis and Atopic Dermatitis to Salt-Soluble Wheat Protein Extract

Biomarkers for atopic dermatitis

Emerging Treatment Options in Atopic Dermatitis: Systemic Therapies

Contact Info

Product

Resources

About